Cytokine and clinical response to Saccharomyces boulardii therapy in diarrhea-dominant irritable bowel syndrome: a randomized trial.

@article{Abbas2014CytokineAC,
  title={Cytokine and clinical response to Saccharomyces boulardii therapy in diarrhea-dominant irritable bowel syndrome: a randomized trial.},
  author={Zaigham Ali Abbas and J Yakoob and Wasim Jafri and Zubair Ahmad and Zahid Azam and Muhammad Waqas Usman and Sara Shamim and Mohammad J. Islam},
  journal={European journal of gastroenterology & hepatology},
  year={2014},
  volume={26 6},
  pages={630-9}
}
INTRODUCTION This preliminary study aimed to investigate the effects of the probiotic Saccharomyces boulardii on proinflammatory and anti-inflammatory cytokines in patients with diarrhea-dominant irritable bowel syndrome (IBS-D). The other objectives were to document any clinical improvement as judged by symptoms, quality of life, and histology. PATIENTS AND METHODS This was a randomized, double blind, placebo-controlled trial in which S. boulardii, 750 mg/day, or placebo was administered for… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS